Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185911 | 1.00 | SLC6A9 (0.36) | SLC6A9SLC6A5OPRD1 | |
| SCHEMBL4185907 | 1.00 | SLC6A9 (0.36) | SLC6A9SLC6A5OPRD1 | |
| SCHEMBL4186222 | 1.00 | SLC6A9 (0.36) | SLC6A9SLC6A5OPRD1 | |
| SCHEMBL4196090 | 1.00 | SLC6A9 (0.36) | SLC6A9SLC6A5OPRD1 | |
| SCHEMBL4196092 | 1.00 | SLC6A9 (0.36) | SLC6A9SLC6A5OPRD1 | |
| SCHEMBL3705038 | 0.89 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL3782491 | 0.83 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL3782500 | 0.83 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL3782488 | 0.83 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL8098119 | 0.82 | OPRD1 (0.34) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013535-A1 | 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | SLC6A9 4382/4885SLC6A5 3965/4885OPRD1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.